Literature DB >> 11772702

Elevation of prolactin levels by atypical antipsychotics.

Peter Turrone1, Shitij Kapur, Mary V Seeman, Alastair J Flint.   

Abstract

OBJECTIVE: Atypical antipsychotics are thought not to elevate prolactin levels. The authors examined data suggesting that atypical antipsychotics do elevate prolactin levels but more transiently than typical antipsychotics.
METHOD: Prolactin levels in 18 male patients with schizophrenia who were receiving atypical antipsychotics were monitored over the 24-hour period following administration of their daily oral dose of risperidone, olanzapine, or clozapine.
RESULTS: The baseline prolactin levels in patients receiving risperidone (mean=27 ng/ml, SD=14) were abnormally high, but baseline prolactin levels in patients receiving olanzapine (mean=9 ng/ml, SD=5) and clozapine (mean=9 ng/ml, SD=5) were not high. All three atypical antipsychotics caused a doubling of prolactin levels over baseline levels 6 hours after medication administration.
CONCLUSIONS: These data suggest that these atypical antipsychotics raise prolactin levels, although the increases with olanzapine did not reach statistical significance. This suggests that the differences in the effects on prolactin levels of atypical and typical antipsychotics are not categorical but lie in the degree and duration of dose-induced prolactin elevation, attributable to the differential binding properties of each drug on pituitary dopamine D(2) receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772702     DOI: 10.1176/appi.ajp.159.1.133

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  31 in total

1.  Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.

Authors:  Jose de Leon; Francisco J Diaz; Richard C Josiassen; George M Simpson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-10       Impact factor: 5.270

2.  The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects.

Authors:  Stefan Cohrs; Cornelia Röher; Wolfgang Jordan; Andreas Meier; Gerald Huether; Wolfgang Wuttke; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

3.  [Not Available].

Authors:  Tamara Pringsheim; Constadina Panagiotopoulos; Jana Davidson; Josephine Ho
Journal:  Paediatr Child Health       Date:  2012-10       Impact factor: 2.253

4.  Side effects of atypical antipsychotics: a brief overview.

Authors:  Alp Uçok; Wolfgang Gaebel
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

5.  Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth.

Authors:  Tamara Pringsheim; Constadina Panagiotopoulos; Jana Davidson; Josephine Ho
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2011-08

6.  Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth.

Authors:  Tamara Pringsheim; Constadina Panagiotopoulos; Jana Davidson; Josephine Ho
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

7.  Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data.

Authors:  Claire Rourke; Kathryn R Starr; Charlie Reavill; Sue Fenwick; Kim Deadman; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-12-07       Impact factor: 4.530

8.  Antipsychotic-induced sexual dysfunction and its management.

Authors:  Yeon Won Park; Yooseok Kim; Jun Ho Lee
Journal:  World J Mens Health       Date:  2012-12-27       Impact factor: 5.400

Review 9.  Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents.

Authors:  Hadine Joffe; Frances J Hayes
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

10.  Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.

Authors:  Daniel A Ollendorf; Amie T Joyce; Malcolm Rucker
Journal:  MedGenMed       Date:  2004-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.